Zacks Research Has Negative Forecast for COO FY2026 Earnings

The Cooper Companies, Inc. (NASDAQ:COO) – Analysts at Zacks Research decreased their FY2026 earnings per share estimates for Cooper Companies in a report issued on Tuesday, September 29th. Zacks Research analyst Team now forecasts that the medical device company will earn $4.53 per share for the year, down from their previous forecast of $4.61. Zacks Research currently has a “Strong Sell” rating on the stock. The consensus estimate for Cooper Companies’ current full-year earnings is $4.53 per share. Zacks Research also issued estimates for Cooper Companies’ Q4 2026 earnings at $1.07 EPS, Q1 2027 earnings at $1.10 EPS, Q2 2027 earnings at $1.17 EPS, Q3 2027 earnings at $1.18 EPS, Q4 2027 earnings at $1.25 EPS, FY2027 earnings at $4.70 EPS, Q1 2028 earnings at $1.23 EPS, Q2 2028 earnings at $1.28 EPS, Q3 2028 earnings at $1.29 EPS and FY2028 earnings at $5.19 EPS.

Several other brokerages have also weighed in on COO. Weiss Ratings upgraded shares of Cooper Companies from a “sell (d)” rating to a “hold (c-)” rating in a report on Friday, September 18th. Wall Street Zen lowered shares of Cooper Companies from a “buy” rating to a “hold” rating in a report on Saturday, September 12th. Stifel Nicolaus set a $70.00 target price on shares of Cooper Companies and gave the company a “buy” rating in a research report on Thursday, September 10th. Citigroup reissued a “neutral” rating and issued a $60.00 price target (down from $80.00) on shares of Cooper Companies in a research note on Thursday, September 10th. Finally, William Blair lowered Cooper Companies from an “outperform” rating to a “market perform” rating in a research report on Thursday, September 10th. Five equities research analysts have rated the stock with a Buy rating, twelve have assigned a Hold rating and two have assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock presently has an average rating of “Hold” and an average target price of $71.47.

Cooper Companies Stock Down 0.9%

Shares of NASDAQ:COO opened at $56.91 on Friday. Cooper Companies has a one year low of $51.01 and a one year high of $89.83. The company has a 50 day moving average of $66.95 and a 200-day moving average of $67.20. The company has a debt-to-equity ratio of 0.23, a current ratio of 1.22 and a quick ratio of 0.73. The stock has a market cap of $10.82 billion, a price-to-earnings ratio of 19.42, a P/E/G ratio of 2.32 and a beta of 0.83.

Cooper Companies (NASDAQ:COO) last announced its quarterly earnings data on Wednesday, September 9th. The medical device company reported $1.15 EPS for the quarter, topping analysts’ consensus estimates of $1.12 by $0.03. The firm had revenue of $1.07 billion during the quarter, compared to analyst estimates of $1.10 billion. Cooper Companies had a return on equity of 10.90% and a net margin of 13.46%.The company’s revenue was up .5% on a year-over-year basis. During the same period last year, the company earned $0.49 earnings per share. Cooper Companies has set its Q4 2026 guidance at 1.050-1.090 EPS and its FY 2026 guidance at 4.510-4.550 EPS.

Institutional Trading of Cooper Companies

A number of large investors have recently made changes to their positions in the company. Envestnet Portfolio Solutions Inc. raised its stake in Cooper Companies by 112.8% during the 2nd quarter. Envestnet Portfolio Solutions Inc. now owns 15,784 shares of the medical device company’s stock worth $1,132,000 after buying an additional 8,366 shares during the period. HBK Investments L P acquired a new position in Cooper Companies in the second quarter valued at about $31,666,000. Sequoia Financial Advisors LLC grew its stake in Cooper Companies by 290.4% in the second quarter. Sequoia Financial Advisors LLC now owns 34,286 shares of the medical device company’s stock valued at $2,459,000 after acquiring an additional 25,504 shares during the period. Tidal Investments LLC increased its holdings in shares of Cooper Companies by 281.4% in the second quarter. Tidal Investments LLC now owns 82,903 shares of the medical device company’s stock worth $5,945,000 after acquiring an additional 61,165 shares in the last quarter. Finally, National Pension Service increased its holdings in shares of Cooper Companies by 9,314.0% in the second quarter. National Pension Service now owns 526,149 shares of the medical device company’s stock worth $37,730,000 after acquiring an additional 520,560 shares in the last quarter. Institutional investors own 24.39% of the company’s stock.

Insider Buying and Selling

In other news, Director Paul Keel acquired 4,701 shares of the firm’s stock in a transaction that occurred on Friday, September 11th. The stock was purchased at an average price of $53.18 per share, for a total transaction of $249,999.18. Following the completion of the acquisition, the director owned 4,701 shares in the company, valued at $249,999.18. This trade represents a ∞ increase in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, Director Lawrence Kurzius bought 10,000 shares of the stock in a transaction on Monday, September 14th. The stock was purchased at an average cost of $53.91 per share, with a total value of $539,100.00. Following the purchase, the director directly owned 21,099 shares of the company’s stock, valued at approximately $1,137,447.09. This represents a 90.10% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders have bought 34,701 shares of company stock valued at $1,880,039 in the last 90 days. 2.08% of the stock is owned by insiders.

Cooper Companies announced that its board has approved a share buyback program on Wednesday, September 9th that allows the company to buyback $3.00 billion in outstanding shares. This buyback authorization allows the medical device company to reacquire up to 22.7% of its shares through open market purchases. Shares buyback programs are usually an indication that the company’s board of directors believes its stock is undervalued.

Key Stories Impacting Cooper Companies

Here are the key news stories impacting Cooper Companies this week:

• Positive Sentiment: Director Kurzius purchased 10,000 COO shares at $54.93 each, investing approximately $549,300. The purchase represented 47% of the director’s prior equity stake and may signal confidence that the stock is undervalued. Cooper Companies Director Kurzius Buys $549,300 in Shares
• Neutral Sentiment: Several law firms, including Rosen and Pomerantz, are soliciting investors in connection with investigations into whether Cooper Companies issued materially misleading information. These announcements do not establish wrongdoing or financial liability, but they add uncertainty and could lead to future legal costs or claims. Rosen Securities Class Action Investigation
• Negative Sentiment: Zacks Research lowered its EPS forecasts across multiple periods, including Q4 2026 to $1.07 from $1.19, FY2026 to $4.53 from $4.61, FY2027 to $4.70 from $4.91, and FY2028 to $5.19 from $5.42. Zacks also maintained a “Strong Sell” rating, reinforcing concerns about slowing earnings momentum.
• Negative Sentiment: The company’s latest results revealed U.S. channel inventory destocking and other unfavorable surprises. The disclosures triggered a major selloff on September 10, eliminating more than $1.7 billion in market value and remaining the primary driver of weakness in COO shares. Cooper Companies Scrutinized Over U.S. Channel Inventory Reductions

About Cooper Companies

CooperCompanies (NASDAQ: COO) is a global medical device company focused on improving vision and advancing women’s health. Its operations are organized primarily through CooperVision and CooperSurgical, which develop, manufacture and distribute products for eye care, fertility and other areas of reproductive health.

CooperVision offers a broad range of contact lenses, including lenses for nearsightedness, farsightedness, astigmatism and presbyopia. Its portfolio includes daily disposable, reusable and specialty lenses, as well as products designed to address the progression of myopia in children and adolescents.